<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>5 Lung and thorax</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part10.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part12.htm">Далее &gt;</a></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="#bookmark10" class="s17" name="bookmark41">Chapter 5</a><a name="bookmark42">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_055.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark10">Lung and thorax</h2></p><p class="s18" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;text-align: left;">Pooja Jain, Katy Clarke, and michael darby</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 13pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.1 <span class="h4">Lung cancer</span></p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.1.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Lung cancer remains the most common cause of cancer death, accounting for 21% of all cancer deaths, in the UK. There are approximately 47,000 new cases per annum and 36,000 deaths. With the reduction in tobacco use in men since the 1990s, lung cancer incidence rates have decreased by almost 10%, broken down into a decrease in men of 31% but conversely an increase in women of 28%. However, it is estimated that nearly 80% of lung cancers are still considered preventable.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">If diagnosed at its earliest stage, more than a 35% of people with lung cancer will survive their disease for five years or more compared to around 5% when diagnosed at a later stage. Unfortunately the majority (72–76%) of patients are diagnosed at stage III or IV.<span class="s22">1</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">With this in mind, lung cancer screening programmes have come to the forefront. Two large studies looked at low dose computed tomography (CT) screening for high- risk patients and both showed a significant reduction in mortality (26% at ten years) from lung cancer in favour of screening.<span class="s22">2,3 </span>Local screening programmes are now being implemented in the UK and this will have a positive impact on the number of patients referred for radical treatments and to a lesser extent on systemic therapies. As yet there is no national screening programme.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Histologically the majority of cases are classified as non-small cell, NSCLC (85– 90%), further subtyped into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The remaining lung cancers are small cell carcinoma, SCLC (10–15%). Worldwide there has been a decline in small cell lung cancer but an increase in adeno- carcinoma which has now become the most common histopathologic type.<span class="s22">4</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">SCLC disseminates early beyond the thorax and will often present with rapid onset symptoms of systemic disease such as weight loss, poor appetite, and deterioration in performance status.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Adenocarcinoma is often the slowest growing lung cancer and can be present as a peripheral lesion for years prior to diagnosis and is often asymptomatic until ad- vanced. Squamous cell and large cell tumours are more rapidly growing, invading lo- cally initially and early tumours often present with haemoptysis. Alternatively, patients who present later with nodal spread may demonstrate locally compressive symptoms such as dysphagia, superior vena cava or airway obstruction before developing sys- temic symptoms.</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Previously the limiting factor for survival, even when diagnosed with early stage dis- ease, depended on a patient’s comorbidities, particularly cardio-respiratory and perform- ance status. With the improvement in surgical techniques and the evolution of stereotactic ablative body radiotherapy and intensity modulated radiotherapy the morbidity and mortality from radical treatments has significantly improved and patients who previously would have been denied curative treatment can be safely and effectively treated.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.1.2 <span class="s29">Diagnosis and staging</span></p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.1.2.1 <span class="s66">Diagnosis</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiological imaging is fundamental in the diagnosis, staging, and follow-up of lung cancer. Most patients still present to lung cancer services with an abnormal chest X-ray, but chest X-ray alone is inadequate for the diagnosis and staging of the disease. Contrast enhanced CT of the chest and upper abdomen, to include liver and adrenals, and <span class="s22">18</span>F-fluorodeoxyglucose positron emission tomography (<span class="s22">18</span>F-FDG PET) are the mainstays of imaging early in the patient pathway (Figure 5.1). Other imaging modalities such as ultrasound (US), magnetic resonance imaging (MRI), and bone scans are used as problem- solving tools in individual cases where staging is still not certain with initial imaging.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Although CT and <span class="s22">18</span>F-FDG PET are highly sensitive in the detection of lung cancer both modalities have relatively low specificity (56–63%). Tissue confirmation is im- portant, although in some cases biopsy is not possible and treatment is based on radiological features alone. Bronchoscopy and biopsy of abnormal tissue is the usual approach; otherwise as a general principle it is best to obtain tissue from the site that will confirm the highest stage of disease (i.e. biopsy metastatic disease before nodal disease before the primary).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 110pt;text-indent: 0pt;text-align: left;"><span><img width="149" height="279" alt="image" src="Image_056.gif"/></span></p><p class="s25" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;"><span class="s24">Fig. 5.1 </span>Coronal images from a <span class="s63">18</span>f-fdG Pet study illustrating avid uptake of fdG in a right upper lobe nodule along with distant nodal metastases.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;"><span><img width="372" height="219" alt="image" src="Image_057.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 5.2 <span class="s25">Ct guided biopsy of right upper lobe nodule.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Metastatic disease is often accessible with US guidance. US guided FNA of neck nodes is a quick and easy procedure which is positive in up to 20% of patients with N2 mediastinal disease, upstaging these patients to N3.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Endobronchial ultrasound (EBUS) has largely replaced mediastinoscopy in the diagnosis of mediastinal nodal disease, although surgical biopsy is sometimes still ne- cessary if the nodes are inaccessible. Endoscopic transoesophageal US may be used for accessing nodes below the level of the carina and occasionally the left adrenal (Figure 5.2). If there is no accessible metastatic or nodal disease CT guided biopsy of the lung primary is performed (Figure 5.3).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;"><span><img width="372" height="245" alt="image" src="Image_058.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 5.3 <span class="s25">endoscopic ultrasound biopsy of a paraoesophageal node.</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Occasionally in a patient who is felt unfit to undergo biopsy, characteristic imaging features and growth in the suspicious lesion over time may be taken as a surrogate marker of malignancy.</p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.1.2.2 <span class="s66">Staging</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Accurate staging of lung cancer is vital for both prognostic and therapeutic decision making.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The current staging system is TNM 8<span class="s22">5 </span>for both SCLC and NSCLC. In order to reflect prognostic and therapeutic similarities various TNM subsets are further characterized in stages I–IV (see Tables 5.1 and 5.2 below).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Table 5.1 <span class="s25">tnm staging of lung cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:14pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">T primary tumour</p></td></tr><tr style="height:26pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">tX</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">Primary tumour cannot be assessed or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t0</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">no evidence of primary tumour</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">tis</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Carcinoma <i>in situ</i><span class="s86">a</span></p></td></tr><tr style="height:36pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;padding-right: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e. not in the main bronchus)<span class="s87">b</span></p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1mi</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">minimally invasive adenocarcinoma<span class="s87">c</span></p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1a</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">tumour 1 cm or less in greatest dimension<span class="s87">b</span></p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1b</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">tumour more than 1 cm but not more than 2 cm in greatest dimension<span class="s87">b</span></p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1c</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">tumour more than 2 cm but not more than 3 cm in greatest dimension<span class="s87">b</span></p></td></tr><tr style="height:78pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t2</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;padding-right: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">tumour more than 3 cm but not more than 5 cm; or tumour with any of the following features<span class="s87">d</span></p><p class="s88" style="padding-left: 14pt;padding-right: 6pt;text-indent: -8pt;line-height: 109%;text-align: left;">◆ <span class="s27">Involves main bronchus regardless of distance to the carina, but without involvement of the carina</span></p><p class="s88" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">◆ <span class="s27">Invades visceral pleura</span></p><p class="s88" style="padding-left: 14pt;text-indent: -8pt;line-height: 109%;text-align: left;">◆ <span class="s27">associated with atelectasis or obstructive pneumonitis that extends to the hilar region either involving part of or the entire lung</span></p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t2a</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">tumour more than 3 cm but not more than 4 cm in greatest dimension</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t2b</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">tumour more than 4 cm but not more than 5 cm in greatest dimension</p></td></tr><tr style="height:47pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t3</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;padding-right: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">tumour more than 5 cm but not more than 7 cm in greatest dimension or one that directly invades any of the following: parietal pleura, chest wall (including superior sulcus tumours) phrenic nerve, parietal pericardium; or separate tumour nodule(s) in the same lobe as the primary</p></td></tr><tr style="height:47pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t4</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">tumour more than 7 cm or of any size that invades any of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina; separate tumour nodule(s) in a different ipsilateral lobe to that of the primary</p></td></tr></table><p class="s80" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: right;">(continued)</p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Table 5.1 <span class="s25">Continued</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3381pt" cellspacing="0"><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">N regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">nx</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">regional lymph nodes cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n0</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">no regional lymph node metastasis</p></td></tr><tr style="height:26pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension</p></td></tr><tr style="height:15pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n2</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)</p></td></tr><tr style="height:26pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n3</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">metastasis in contralateral mediastinal, contralateral hilar, ipsilateral, or contralateral scalene, or supraclavicular lymph node(s)</p></td></tr><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">m0</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">no distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">m1</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">distant metastasis</p></td></tr><tr style="height:26pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">m1a</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 112%;text-align: left;">Separate tumour nodule(s) in a contralateral lobe; tumour with pleural or pericardial nodule(s) or malignant pleural or pericardial effusion<span class="s87">e</span></p></td></tr><tr style="height:15pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">m1b</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Single extrathoracic metastasis in a single organ<span class="s87">f</span></p></td></tr><tr style="height:15pt"><td style="width:22pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">m1c</p></td><td style="width:301pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">multiple extrathoracic metastases in a single or multiple organs</p></td></tr></table><p class="s21" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">notes</p><p class="s83" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;"><span class="s89">a </span><span class="s90">tis includes adenocarcinoma </span>in situ <span class="s21">and squamous carcinoma </span>in situ<span class="s21">.</span></p><p class="s89" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: left;">b <span class="s90">the uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as t1a.</span></p><p class="s89" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: left;">c <span class="s90">Solitary adenocarcinoma (not more than 3 cm in greatest dimension), with a predominantly lepidic pattern and not more than 5 mm invasion in greatest dimension in any one focus.</span></p><p class="s89" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: left;">d <span class="s90">t2 tumours with these features are classified t2a if 4 cm or less, or if size cannot be determined and t2b if greater than 4 cm but not larger than 5 cm.</span></p><p class="s89" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: left;">e <span class="s90">most pleural (pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is non-bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumour, the effusion should be excluded as a staging descriptor</span></p><p class="s89" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">f <span class="s90">this includes involvement of a single non-regional node.</span></p><p class="s21" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: left;">reproduced with permission from Sobin lH, Gospodarowicz mK, Wittekind CH. <i>UICC TNM Classification of Malignant Tumours</i>. 8th ed. © 2017 Wiley Blackwell.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s91" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">T stage <span class="p">T stage depends upon the size of the primary tumour and any sites of local invasion. Both of these are most accurately assessed with CT scanning due to its higher spatial resolution compared to PET or MRI.</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The primary tumour should be measured on CT lung windows setting across its largest possible diameter. Although distinguishing T1 from T2 tumours is unlikely to have any impact upon treatment, the various subdivisions have been shown to have prognostic importance. Accurately identifying T3 and T4 tumours can have important ramifications, and although CT is the mainstay in some specific circumstances other modalities are used in addition. US may be useful in possible direct chest wall invasion,</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 5.2 <span class="s25">Summary of tnm staging with respect to stage groups</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:14pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 22pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">No</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">N1</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">N2</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">N3</p></td></tr><tr style="height:15pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s92" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T1</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 19pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">Ia</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 22pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IIB</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIa</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIB</p></td></tr><tr style="height:15pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s92" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T2a</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 18pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IB</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 22pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IIB</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIa</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIB</p></td></tr><tr style="height:15pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s92" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T2B</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 21pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IIa</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 22pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IIB</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIa</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIB</p></td></tr><tr style="height:15pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s92" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T3</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 20pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IIB</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 25pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IIIa</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIB</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIC</p></td></tr><tr style="height:15pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s92" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T4</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IIIa</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 25pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IIIa</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIB</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IIIC</p></td></tr><tr style="height:15pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s92" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1a</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 24pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IVa</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 25pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IVa</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IVa</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IVa</p></td></tr><tr style="height:15pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s92" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1b</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 24pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IVa</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 25pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IVa</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IVa</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IVa</p></td></tr><tr style="height:15pt"><td style="width:41pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s92" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1c</p></td><td style="width:63pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IVB</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 25pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">IVB</p></td><td style="width:65pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IVB</p></td><td style="width:89pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 26pt;text-indent: 0pt;text-align: left;">IVB</p></td></tr></table><p class="s21" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 111%;text-align: left;">Source: data from amin mB et al. (eds.) <i>AJCC Cancer Staging Manual </i>(8th edition). Springer International Publishing: american Joint Commission on Cancer; 2017.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">and MRI is used in the assessment of superior sulcus tumours due to its superior soft tissue characterization when compared to CT.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT should be interpreted with caution in cases of suspected direct mediastinal in- vasion where it has been shown to have a false positive rate of up to 33%, and direct surgical inspection is still occasionally necessary in this situation.</p><p class="s91" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">N stage <span class="p">CT assessment of mediastinal nodal disease is based on size, with a cut-off of 1 cm in the shortest axis, traditionally taken as the boundary between normal and abnormal. This is a very blunt tool, however, with sensitivity and specificity estimated at 60% and 77% respectively.</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">PET/CT, which relies on the uptake and concentration of the radioactive tracer <span class="s22">18</span>F- FDG by cancer cells, is a much more accurate way to assess the mediastinal nodes, with sensitivity and specificity of 79% and 91% respectively. <span class="s22">18</span>F-FDG PET/CT is there- fore now routinely used for mediastinal nodal staging in all cases other than those with obvious metastatic disease on the original CT scan. Although high, the specificity of <span class="s22">18</span>F-FDG PET/CT is not 100%, however, and other inflammatory processes in the mediastinum, such as infection, can result in a positive PET scan. Tissue confirmation of malignancy, usually via endobronchial or endoscopic US, is therefore still necessary in cases of <span class="s22">18</span>F-FDG avid mediastinal nodes.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Conversely, in cases where there are visible but <span class="s22">18</span>F-FDG non-avid mediastinal nodes it is wise to sample these to confirm that they are not involved before putting a patient through surgery.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The gold standard for staging the mediastinum has traditionally been mediastinoscopy. Paratracheal (stations 2R, 2L, 4R, 4L), pretracheal (stations 1 and 3), and anterior subcarinal (station 7) nodes are accessible. Although invasive, it can be done as an out- patient procedure with minimal morbidity (2.3%) and mortality (0.05%). The average false negative rate of mediastinoscopy is 9%. Many papers have shown similar accuracy with EBUS-TBNA (transbronchial needle aspiration) and recent American College of</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Chest Physician guidelines have recommended EBUS-TBNA as the best first test for nodal staging in patients with radiologically suspicious nodes.<span class="s22">6</span></p><p class="s91" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">M Stage <span class="p">Lung cancer can metastasize to anywhere in the body, but the most common sites are elsewhere in the lung, the pleura, liver, adrenals, bone, and brain. The latest version of the TNM staging system for the first time distinguishes intrathoracic metastases from those outside the chest as well as single from multiple metastases.</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: right;">As with nodal metastases <span class="s22">18</span>F-FDG PET/CT has been shown to be considerably more sensitive than CT in the detection of distant metastases (Figure 5.4). Combining nodal and distant metastatic disease together PET will upstage up to 18% of patients with lo- calized disease on CT scanning alone. <span class="s22">18</span>F-FDG PET/CT has therefore become routine in the assessment of patients who are found on CT to have radically treatable disease. Due to the high background levels of glucose uptake in the brain, <span class="s22">18</span>F-FDG PET/ CT is not as accurate for brain metastasis. There is still much debate as to the role of routine brain imaging in asymptomatic patients prior to treatment but current NICE recommendations suggest considering brain imaging (either CT or MRI) in patients</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">with N2 or T3 disease being considered for radical treatment.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Imaging for patients with known lung cancer and symptoms suggesting metastatic disease is performed on an individual basis. MRI spine is usually recommended for the investigation of new onset back pain as it allows assessment of not just the verte- brae but also any threat to the cord. Plain film is usually adequate for those with ap- pendicular bone pain, but DMSA bone scan, CT, and MR are all more sensitive should further investigation be felt necessary.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.1.3 <span class="s29">Imaging for radiotherapy planning</span></p><p class="s28" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.1.3.1 <span class="s66">Radical radiotherapy</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy has a major role in the treatment of lung cancers both in curative and palliative settings, and can be useful in all stages regardless of histology. High doses are essential for local control and cure. According to the NLCA 2017 report there has</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="408" height="156" alt="image" src="Image_059.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s25" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;"><span class="s24">Fig. 5.4 </span>axial images from a <span class="s63">18</span>f-fdG Pet/Ct study showing avid uptake of fdG in a left upper lobe non-small cell bronchial carcinoma and uptake in the adjacent vertebral body upstaging the disease advanced stage.</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">been a significant increase in treatment with curative intent for NSCLC, with 81% of patients with stage I-II disease and PS 0-2 receiving either surgery or radiotherapy.<span class="s22">4</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">High-dose radiation therapy delivered either as SABR,<span class="s22">8 </span>accelerated in the CHART schedule or conventional fractionation is used as the primary management for medic- ally inoperable stages I and II NSCLC. Radical radiotherapy is also delivered alongside chemotherapy as part of combined modality treatment, in suitable stage III NSCLC, in both concurrent and sequential settings. Adjuvant radiotherapy in patients with positive resection margins is used to reduce the risk of local recurrence. This can be particularly challenging as it can be difficult to reliably identify the area at risk, using pre- and postoperative images. Radical radiotherapy, especially SABR to extracranial metastases, has also been shown to improve survival in patients with oligometastatic stage IV disease.<span class="s22">9</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Delivery of modern radiotherapy requires 4DCT for advanced planning and veri- fication techniques. These techniques help improve local control by: (1) improving target volume definition; (2) capturing respiratory motion accurately; (3) improving conformality of treatment with the ability to create steep dose gradients between tu- mour and organs at risk (OAR); and (4) improved accuracy of treatment delivery by better verification to minimize geographical misses. Radiotherapy with palliative in- tent is less reliant on these technological advances.</p><p class="s28" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.1.3.2 <span class="s66">Treatment planning process</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Patients are scanned in a supine position with their arms supported above their heads. Techniques for immobilizing the patient vary, including polystyrene bead-filled bags shaped by vacuum suction or boards with fixed armrests attached to support the pa- tient. An arm down position, with immobilization for the shoulders provided with a five-point fixation mask of the head and upper thorax maybe preferred in patients with superior sulcus or apical tumours or in patients who are unable to maintain a reprodu- cible position with their arms up due to loss of shoulder mobility.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A CT scan of the whole lung from apex to diaphragm is taken with the patient in the treatment position. For modern treatment planning systems the slice width should ideally be 2 mm. For patients with hilar or lower lobe tumours which can move signifi- cantly with respiration a 4D CT is recommended to take into account individual specific tumour motion and avoid the use of generic planning margins. Intravenous contrast administered for planning scans allows better definition of tumours close to the hilum.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">PET based tumour delineation can improve the accuracy of tumour outlining, es- pecially when there is adjacent collapse or consolidation. Trials are underway to boost PET avid areas to reduce the risk of local recurrence. However, fusion of images is complicated by differences in position of the patient between the scans and by respira- tory movement which may be significant in a PET image series which has taken 20 min. to obtain during tidal breathing compared with a helical CT series done rapidly in a single breath hold.</p><p class="s28" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.1.3.3 <span class="s66">Respiratory motion</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Tumour motion from breathing during treatment is a major challenge in planning lung radiotherapy. With multidetector CT imaging there is a quick ‘snapshot’, with the</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="123" alt="image" src="Image_060.jpg"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 5.5 <span class="s25">right lower zone cancer as seen on a standard planning scan, In blue is the ItV contour capturing respiratory motion based on 4d Ct scan. (a) Shows coronal view.</span></p><p class="s25" style="padding-left: 11pt;text-indent: 0pt;line-height: 10pt;text-align: left;">(b) Shows sagittal view.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">result that the extent of respiratory motion is not captured so that the target volume derived from this single point in time may geographically miss the tumour as it moves with respiration (Figure 5.5).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Studies measuring real time tumour motion describe a complex motion ‘hyster- esis’ which is a combination of motion in all three axes, rather than a simple longi- tudinal motion.<span class="s22">10 </span>Generally tumours in the lower lobes and nodes around the hilum and subcarina tend to show more respiratory motion than in upper lobes. Voluntary breath-holding techniques, deep inspiration breath- hold, and active breath control are physical techniques which theoretically help in limiting tumour motion but have not been very successful as all rely on patient compliance and require levels of breath control which tends to be difficult for the majority of lung cancer patients.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">It is usually easier to incorporate respiration in planning using a 4D CT. CT images are acquired over the whole respiratory cycle and sorted into ‘bins’ for each phase of respiration, so that the position of the tumour can be pinpointed for each phase. With a ‘gating’ radiotherapy technique the linear accelerator is set to function in an on-off mode coordinated with the phase of respiration for which the radiotherapy plan has been produced. With ‘tracking’ techniques there is continuous delivery throughout the breathing cycle of a 4D treatment plan which takes account of the varying position of the tumour over time.</p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.1.3.4 <span class="s66">Contouring for radiotherapy planning</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Contouring of the target volume and OAR is performed on each axial slice of the planning CT.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The gross tumour volume (GTV) is delineated, using both lung and soft tissue win- dows to define the tumour volume accurately (Figure 5.6). When 4D CT is used for planning, the tumour needs to be contoured on all individual phases to incorporate the respiratory motion accurately. In some cases a maximum intensity projection (MIP) scan can be created from all the phases. It is essential that the tumour contours are checked against individual phases to ensure there is no geographical miss, espe- cially as MIPs are not very reliable when the tumour motion is large or close to the diaphragm. In these cases the internal margin is incorporated within the GTV contour and this is called internal target volume (ITV).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="167" alt="image" src="Image_061.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 5.6 <span class="s25">(a) Peripheral tumour with GtV outline marked on mediastinal window setting.</span></p><p class="s25" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">(b) the same peripheral tumour: this will often appear larger on lung window settings.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The GTV is then grown by a margin of 5–8 mm depending on histology, to a clin- ical target volume (CTV). As CTV margin is for microscopic extension, if a tumour is known not to invade nearby OAR, this should be amended manually. Growth of the volume to produce planning target volume (PTV) is usually achieved by an algorithm in the planning system to permit 3D growth in accordance with preset margins which must never be edited even if it is going into an OAR such as spinal cord or air as this margin is used to account for set-up variation (Figure 5.7).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Shielding conforming to the PTV is achieved by using multileaf collimation (MLC). To ensure optimal positioning of the beams the planning system uses a beam’s eye view (BEV) which allows the reconstructed image of the patient to be rotated on the com- puter screen. In this way the MLC can be set up to conform closely to the PTV, for each individual beam, while viewing proximity to OARs such as spinal cord (Figure 5.8).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="408" height="212" alt="image" src="Image_062.jpg"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 5.7 <span class="s25">Coronal view.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">It is also important to outline OARs on the planning scan. The entire organ is con- toured if a volumetric dosimetric constraint is used such as V20, volume of lungs get- ting 20 Gy or more. If a point or max dose is used then the OARS can be contoured 3–5 cm above and below the PTV as long as a coplanar beam arrangement is used. This is essential for IMRT/VMAT planning as detailed later.</p><p class="s28" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.1.3.5 <span class="s66">Dose-limiting factors in lung radiotherapy</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">For lung radiation the dose-limiting factors traditionally are pneumonitis, oesopha- gitis, and spinal cord tolerance. However, as demonstrated by the dose escalation RTOG 0617 trial, there is increasing evidence of the importance of cardiac irradi- ation and the morbidity it can cause.<span class="s22">11 </span>Contouring OARs enables dose volume histo- grams (DVHs) to be generated that can be used to compare alternative radiotherapy plans with regard to not only the radiation dose to PTV but also the relative volumes of OAR receiving radiation doses approaching defined tolerance levels (Figure 5.9). Other OARs such as brachial plexus, airways, and main vessels (aorta, superior vena cava) should be contoured when planning SABR.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Symptomatic radiation pneumonitis occurs in 5–15% of patients treated with radical radiotherapy doses and depends upon total dose, volume of lung irradiated,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="314" alt="image" src="Image_063.gif"/></span></p><p class="s93" style="text-indent: 0pt;text-align: left;">(a)</p><p class="s93" style="text-indent: 0pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s93" style="text-indent: 0pt;text-align: left;">(a)</p><p class="s93" style="text-indent: 0pt;text-align: left;">(b)</p><p class="s93" style="text-indent: 0pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s93" style="text-indent: 0pt;text-align: left;">(b)</p><p class="s93" style="text-indent: 0pt;text-align: left;">(c)</p><p class="s93" style="text-indent: 0pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s93" style="text-indent: 0pt;text-align: left;">(c)</p><p class="s93" style="text-indent: 0pt;text-align: left;">(d)</p><p class="s93" style="text-indent: 0pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s93" style="text-indent: 0pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 5.8 <span class="s25">radiotherapy plan. (a) three beam’s eye view (BeV) images projected onto body showing orientation of fields. (b) digitally reconstructed radiograph (drr) of anterior field. PtV on each slice is marked in red. Blue lines show how multileaf collimator</span></p><p class="s25" style="padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">(mlC) conforms to target volume. (c) drr for right anterior oblique field without mlC markings. (d) drr for right posterior oblique filed without mlC markings.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="409" height="229" alt="image" src="Image_064.jpg"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: justify;">Fig. 5.9 <span class="s25">dose volume histogram for a patient receiving prescribed dose of 55 Gy. the volume of remaining lung (whole lung subtract PtV) receiving 20 Gy (V20) is approximately 20%.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">fraction size, and use of chemotherapy. Presence of pulmonary fibrosis, particularly UIP, increases the risk of pneumonitis. Refinement of data on normal tissue compli- cation probabilities over the past decade has led to the use of specific parameters to assess the risk of pneumonitis and guide decisions about radiotherapy.<span class="s22">12 </span>The higher the percentage of lung volume receiving &gt;20 Gy (V20), and mean lung dose (MLD), the higher the risk of pneumonitis.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Acute oesophagitis is another commonly recognized complication of radical radi- ation doses to the chest although with lower risk of fatal toxicity or long-term sequelae than lung damage. In practice increasing the length of the oesophagus, within the treatment field, increases the risk of symptomatic oesophagitis, especially for lengths</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">&gt;12 cm.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For spinal cord, maximum point doses are used as it is essential not to exceed tol- erance dose at any single level within the cord. The aim is to stay below 44 Gy in 2-Gy fractions although tolerance may be lowered with altered fractionation.</p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.1.3.6 <span class="s66">Intensity modulated/volumetric arc radiation therapy</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">This approach to planning involves specifying objectives such as desired dose to PTV and dose constraints for OARs which is used by a planning algorithm to derive the optimal plan. Invariably the plans can achieve tight dose constraints around OARs by modulating the intensity of the radiation beam (Figure 5.10).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Functional imaging with PET and perfusion MRI scans can provide information on the distribution of functional lung tissue as many lung cancer patients will have emphysematous destruction or poorly perfused areas of lung which are therefore less important to spare. IMRT/VMAT planning can theoretically help in creating plans that can differentially spare irradiation of healthy lung. This opens the way for more</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="387" height="115" alt="image" src="Image_065.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 5.10 <span class="s25">(a) 3-d plan with fixed beam angles for an apical tumour (b) same tumour planned with Vmat showing better conformality of higher isodoses to tumour (red and orange colour-wash) with better sparing of cord (turquoise and indigo colour-wash).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">sophisticated analysis of lung DVHs than is currently available where all lungs are as- sumed to be equal.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The drawbacks of lung IMRT, however, are that: (1) a larger total volume of lung may receive low dose radiation and (2) there are often sharp dose gradients. This is a particular problem with tightly conforming fields such that the respiratory motion may cause geographical miss in the absence of advanced treatment verification tech- niques like cone beam CT (CBCT).</p><p class="s28" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.1.3.7 <span class="s66">Treatment verification</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Treatment verification is essential to confirm that the treatment is delivered as planned. Modern linear accelerators have the capability of obtaining CBCT imaging which provides detailed anatomical information. This represents a significant advance on treatment verification. The planning scan is matched to the CBCT for treatment verification. Depending on doses to OARs, the match can be to the critical OAR such as spine, chest wall (surrogate for plexus), or the tumour itself (Figure 5.11).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CBCT can be converted to 4D CBCT, similar to 4D CT, and can provide a check of tumour motion during treatment. Sometimes when 4D CT cannot be acquired at the time of planning due to issues such as erratic or slow breathing, then 4D CBCT is useful in creating an appropriate ITV, thereby avoiding geographical miss and/or in- appropriately large margins.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">With improved anatomical verification it is easy to identify changes in the lung par- enchyma during treatment such as reinflation of a collapse, development of a pleural effusion, or tumour shrinkage (Figure 5.12). Identifying such changes avoids geo- graphical miss and gives an opportunity to readjust the treatment plan if there are dosimetric consequences for the tumour or OARs.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.1.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The objectives of follow-up imaging after radiotherapy for lung cancer are threefold: to assess response to treatment; to monitor toxicity (both acute and late in onset); and to detect progression or relapse when it occurs.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In trials RECIST criteria for response assessment usually require two CT scans, a month apart, with the first done a minimum of six weeks following completion of</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="409" height="314" alt="image" src="Image_066.jpg"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 5.11 <span class="s25">Cone beam Ct taken prior to radiotherapy delivery to match accurately to tumour as the tumour location is close to brachial plexus (green).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">radiotherapy, although outside of clinical trials, usually, a single investigation is under- taken. Reduction in tumour or nodal mass can be measured but it is often difficult in the presence of pneumonitic changes, or associated collapse or consolidation, to categorize response definitively. There continues to be debate about the need for and frequency of further follow-up scans which should be determined on an individual patient basis, influenced by whether second-line therapy would be feasible in case of progressive disease or relapse.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The radiological changes of acute pneumonitis commonly peak at about three months and as well as monitoring clinical symptoms and pulmonary function it may be worth repeating imaging with chest X-ray, keeping CT in reserve for concerns, sev- eral months later to assess resolution of this toxicity (Figure 5.13).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Tumour response after treatment assessed by PET is much more powerfully correl- ated with survival than response measured by CT.<span class="s22">13 </span>This has raised the potential role of PET in early monitoring of patients to allow response adapted therapy similar to approaches being developed in lymphoma.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">5.2 <span class="h4">Other thoracic malignancies</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">This chapter has thus far focused on radiotherapy planning for non-small cell lung cancer; however, the same principles can be applied to treating other thoracic malignancies.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 21pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="203" height="179" alt="image" src="Image_067.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="195" height="172" alt="image" src="Image_068.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="200" height="172" alt="image" src="Image_069.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 5.12 <span class="s25">(a) CBCt overlayed over planning scan showing changes in post pneumonectomy fluid space during treatment (purple represents changes seen on CBCt and green represents planning scan). Change in post pneumonectomy space is causing a lateral shift on the airways (green) which is likely to impact on PtV position. (b) Planning Ct scan. (c) Cone beam Ct.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 87pt;text-indent: 0pt;text-align: left;"><span><img width="223" height="223" alt="image" src="Image_070.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 5.13 <span class="s25">Image from Ct study of a patient previously treated with radical radiotherapy for a right upper lobe bronchial carcinoma. the scan demonstrates changes in lung parenchyma consistent with radiation fibrosis.</span></p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.2.1 <span class="s29">Small cell lung cancer</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">SCLC is characterized by an aggressive disease course with development of early meta- static disease despite often apparently limited thoracic disease. Combination chemo/ radiotherapy remains the mainstay of treatment using a concurrent chemoradiotherapy protocol.<span class="s22">14</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">There is also a benefit from consolidation thoracic radiotherapy in advanced disease, with a significant improvement in two-year survival and progression free survival.<span class="s22">15</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Because of the high rates of brain metastases the role of prophylactic cranial irradiation has been investigated in both limited and extensive stage small cell lung cancer. Doses varied from 20 Gy/5 fractions to 30 Gy/10 fractions within the studies. Initial studies did show improvement in both survival and reduction in the occurrence of brain metastases in patients both in the palliative and radical setting. However, this comes with significant toxicities such as severe fatigue, short-term memory loss, and alopecia, and recent studies have shown that this could be detrimental to patients in the extensive stage setting.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.2.2 <span class="s29">Thymoma</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Thymoma is a rare tumour arising from the epithelial cells of the thymus and is most commonly seen as a mass in the anterior mediastinum. Pathologically this represents a spectrum of disease ranging from the relatively benign type A thymomas which take many years to grow and have very low recurrence rates, to a type C which often be- haves more like NSCLC.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The main stay of treatment remains surgical resection. However, adjuvant radio- therapy may be indicated when resection margins are positive, for higher stage disease and for the more aggressive pathological subtypes of thymoma. Radical radiotherapy and chemoradiotherapy, concurrent or sequential, are also used when thymomas are localized but surgically unresectable. In metastatic disease chemotherapy is the main treatment option.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Radiotherapy to the anterior mediastinum can be challenging both in terms of achieving adequate dosing and avoiding OAR. Traditional beam arrangements such as anterior oblique fields or APPA fields with a lateral beam often lead to plans exceeding safe lung tolerance parameters. However, using the advanced planning techniques de- scribed earlier in the chapter we can now avoid this.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.2.3 <span class="s29">Pleural mesothelioma</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Malignant pleural mesothelioma continues to increase in incidence and presents with diffuse pleural involvement for which treatment is palliative rather than curative.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Systemic chemotherapy with a platinum and pemetrexed doublet remains the only treatment that has shown a survival benefit in phase three randomized controlled trials in the mesothelioma population.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">5.3 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Lung cancer is the commonest cause of cancer death.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Radical radiotherapy can potentially cure lung cancer, especially in early stage disease.</span></p><p class="s23" style="padding-top: 4pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Local control rates following radical radiotherapy are related to the dose de- livered and for early lung cancers can be in excess of 80–90% especially if treated with SABR.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Functional imaging with PET and 4D imaging with CT should contribute to im- proved target volume definition with reduced risk of geographical miss.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Accurate defined target volumes and OAR are essential for advanced planning techniques such as IMRT/VMAT.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Continued monitoring of normal tissue complication rates will better inform the use of DVH parameters to guide decisions about radiotherapy plans.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Improved treatment verification techniques are evolving rapidly, with real-time electronic portal imaging, kV imaging on LINACs, and CBCT; these minimize geographical miss and allow the use of smaller planning margins.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">1. <a href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer" style=" color: #231F20; font-family:&quot;Palatino Linotype&quot;, serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 8.5pt;" target="_blank">Statistics from Cancer Research UK </a><a href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer" class="a" target="_blank">https://www.cancerresearchuk.org/health- </a><a href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer" target="_blank">professional/cancer-statistics/statistics-by-cancer-type/lung-cancer</a></p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">2. <b>The National Lung Screening Trial Research Team (2011). </b>Reduced lung-cancer mortality with low-dose computed tomographic screening. <i>New England Journal of M</i>e<i>dicine</i>,</p><p class="s75" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;">365<span class="s74">(5): 395–409.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">3. <b>De Koning H</b>, <b>Van Der Aalst C</b>, <b>Ten Haaf K, et al. </b>(2018). Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. <i>Journal of Thoracic Oncology</i>, <b>13</b>(10): S185.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">4. <b>Alberg AJ, Ford JG, Samet JM. (2007). </b>Epidemiology of lung cancer: ACCP evidence- based clinical practice guidelines, 2nd ed. <i>Chest</i>. <b>132: </b>29S–55S.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">5. <b>Goldstraw P</b>, <b>Chansky K</b>, <b>Crowley J, et al. </b>(2016). The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. <i>Journal of Thoracic Oncology</i>, <b>11</b>(1): 39–51.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">6. <b>Silvestri GA</b>, <b>Gonzalez AV</b>, <b>Jantz MA, et al. </b>(2013). <b>Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer. </b>3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>, <b>143</b>(Suppl</p><p class="s74" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5): e211S–e250S.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">7. <b>National Lung Cancer Audit annual report </b>(2017) (for the audit period 2016): <i>National Lung Cancer Audit Report </i>(2014) Report for the audit period 2013.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">8. <b>Chang J</b>, <b>Senan S</b>, <b>Paul M, et al. </b>(2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Oncology</i>, <b>16</b>(6): 630–637.</p><p class="s74" style="padding-top: 1pt;padding-left: 16pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9. <b>Juan O</b>, <b>Popat S </b>(2017). Ablative therapy for oligometastatic non-small cell lung cancer.</p><p class="s74" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><i>Clinical Lung Cancer</i>, <b>18</b>(6): 595–606.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: justify;">10. <b>Seppenwoolde Y</b>, <b>Shirato H</b>, <b>Kitamura K, et al. </b>(2002). Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. <i>International Journal Radiation Oncology. Biology. Physics</i>, <b>53</b>(4): 822–834.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: justify;">11. <b>Chun S</b>, <b>Hu C</b>, <b>Choy H, et al. </b>(2017). Impact of intensity-modulated radiation therapy technique for locally advanced non–small-cell lung cancer: a secondary analysis of</p><p class="s74" style="padding-top: 4pt;padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">the NRG oncology RTOG 0617 randomized clinical trial. <i>Journal of Clinical Oncology</i>,</p><p class="s75" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">35<span class="s74">(1): 56–62.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">12. <b>Seppenwolde Y</b>, <b>Lebesque JV</b>, <b>de Jaeger K, et al. </b>(2003). <b>Comparing different NTCP models that predict the incidence of radiation pneumonitis. </b>Normal tissue complication probability. <i>International Journal Radiation Oncology. Biology. Physics</i>, <b>55</b>(3): 724–735.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">13. <b>Patz EF</b>, <b>Connolly J</b>, <b>Herndon J </b>(2000). Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. <i>American Journal of Roentgenology</i>,</p><p class="s75" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">174<span class="s74">: 769–774.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">14. <b>Turrisi AT</b>, <b>Kim K</b>, <b>Sause WT, et al. </b>(1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. <i>New England Journal of Medicine</i>, <b>340</b>(4): 265–271.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">15. <b>Slotman BJ</b>, <b>van Tinteren H</b>, <b>Praag JO, et al. </b>(2015). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. <i>Lancet</i>, <b>385</b>(9962): 36–42.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part10.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part12.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
